Sun Pharmaceutical Industries has announced the resolution of its litigation with U.S.-based Incyte Corporation, marking a significant step toward clearing legal uncertainties that have hovered over the company’s operations. The settlement, involving terms that remain confidential, effectively ends a dispute centered on intellectual property rights and commercial interests. For Sun Pharma, the agreement removes a potential overhang on its growth plans in the critical U.S. market while reinforcing its commitment to collaborative business practices.